source
- Boehringer Ingelheim pauses phase 1 trial of BI 3031185 in Japan to investigate safety eventBoehringer Ingelheim has placed a phase 1 study of its investigational oral small‑molecule candidate BI 3031185 on voluntary hold after a safety event was reported. The trial, which began in early…
- Tolerance Bio secures up to $260 M for thymus‑targeting fusion protein, moves into Phase 2 trialsTolerance Bio, a Philadelphia biotech founded in October 2024, has signed a licensing agreement to acquire rights to NeoImmuneTech’s long‑acting IL‑7 fusion protein, efineptakin alfa, for up to $26…